Clinical Trial Update: A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD) [Phase 2]

View source ↗

Summary

A Phase 2 cross-over study comparing once-daily and twice-daily TD-4208 in COPD, completed with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• TD-4208 (TD-4208)

Snippet

Sponsor: Mylan Inc. | Conditions: Chronic Obstructive Pulmonary Disease, COPD | Phase 2 | Status: COMPLETED | Results posted: 2016-12-08